[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Emory University\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":615},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,223,0,25,[9,55,79,105,126,145,169,188,209,231,252,274,297,317,358,376,398,421,446,470,502,522,545,568,594],{"id":10,"slug":4,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":20,"enrollmentInfo":21,"targetDuration":4,"studyType":24,"phases":25,"briefSummary":27,"conditions":28,"keywords":32,"overallStatus":42,"whyStopped":4,"lastUpdateSubmitDate":43,"lastUpdatePostDateStruct":44,"startDateStruct":47,"completionDateStruct":49,"leadSponsor":51,"locationsCount":54},"100053577",false,"NCT07697664","Moving Yourself in Space and Time: MYSTIC","Moving Yourself in Space and Time Identifying Spatial and Temporal Components of Complex Rhythmic Movement Training for People With Parkinson's Disease and Cognitive Impairment","MYSTIC","Inclusion Criteria for Young adults and adults with normal cognition (NC):\n\n* 18 to 35 Years old\n* Montreal Cognitive Assessment (MoCA) score of 26 to 30\n\nInclusion Criteria for Older Adults:\n\n* 50 to 79 with or without MCI\n* 50 to 79 years old with Parkinson's disease (PD), who do NOT have impaired decision-making capacity\n* Participants who achieve less than 150 minutes moderate or 75 minutes vigorous aerobic activity per week (as per the US Department of Health and Human Services (HHS)),\n\nExclusion Criteria for all groups:\n\n* Acute medical illness requiring hospitalization;\n* Uncontrolled congestive heart failure;\n* History of stroke in the past three years;\n* Inability to perform study procedures;\n* Medical or physical conditions that would preclude participation (e.g., severe arthritis or mobility problems, uncontrolled hypertension or diabetes, renal failure, history of angina with activity);\n* On medications that could adversely affect cognition, e.g., antipsychotics, opioids, stimulants, chemotherapy, and neurologic prescriptions to treat Multiple Sclerosis. When applicable, enrollment will be delayed until dosages are stable on e.g., Aricept, Namenda, anticholinesterase inhibitors, for at least 3 months\n* Psychotic disorders\n* Confounding neurologic conditions \\[e.g., active central nervous system (CNS) opportunistic infections, seizure disorders, head injury with loss of consciousness \\>30 minutes, intracranial neoplasms, stroke with neurological or neuropsychiatric sequelae\\]\n* Substance Use Disorder, Major Depressive Disorder, and Generalized Anxiety Disorder within six months of evaluation.\n* Inability to provide informed consent",true,"ALL","18 Years","79 Years",{"count":22,"type":23},210,"ESTIMATED","INTERVENTIONAL",[26],"NA","This study is being done to answer the question: Do people with Parkinson's benefit from a new stepping therapy, and how do people with Parkinson's best learn new steps and rhythms set to music? Researchers will also compare individuals with Parkinson's Disease with people with Mild Cognitive Impairment, and with people with neither of these conditions.\n\nThe purpose of this study is to identify principles of human-music interactions to establish underlying guiding theories for application to music-based rehabilitation for older populations with neurodegenerative disease, leading to more refined and targeted music-based rhythmic movement therapies.",[29,30,31],"Parkinson's Disease (PD)","Alzheimer's Disease (AD) and Related Disorders","Older Adults (60 - 85 Years Old)",[33,34,35,36,37,38,39,40,41],"Dance","Music","Therapy","Rehabilitation","Neurodegenerative","Parkinson's","Alzheimer's","Motor learning","Motor control","RECRUITING","2026-07-07",{"date":45,"type":46},"2026-07-13","ACTUAL",{"date":48,"type":46},"2022-03-25",{"date":50,"type":23},"2028-12",{"name":52,"class":53},"Emory University","OTHER",1,{"id":56,"slug":4,"hasResults":11,"nctId":57,"briefTitle":58,"officialTitle":58,"acronym":4,"eligibilityCriteria":59,"healthyVolunteers":11,"sex":18,"minAge":60,"maxAge":19,"enrollmentInfo":61,"targetDuration":4,"studyType":24,"phases":62,"briefSummary":63,"conditions":64,"keywords":66,"overallStatus":70,"whyStopped":4,"lastUpdateSubmitDate":71,"lastUpdatePostDateStruct":72,"startDateStruct":74,"completionDateStruct":76,"leadSponsor":78,"locationsCount":54},"100636189","NCT07562451","Assessing Molecular Mechanisms and Effects of Music Therapy in Youth With Sickle Cell Disease Using Single-cell RNA-sequencing","Inclusion Criteria:\n\n* Diagnosed with SCD\n* English fluency (for survey completion)\n* Have access to a personal electronic device (e.g., phone, tablet) with access to the internet\n* Meet the criteria for chronic pain defined by the International Association for the Study of Pain (IASP). IASP defines chronic pain as pain that is both:\n\n  1. Persistent or recurrent for ≥ 3 months\n  2. is associated with significant emotional distress or functional disability.30\n\nExclusion Criteria:\n\n* Major hearing deficiency or medical condition in which listening to music may be contraindicated (e.g., reflex epilepsy).","8 Years",{"count":7,"type":23},[26],"The goal of this clinical trial is to evaluate whether a 4-week music therapy (MT) intervention can reduce chronic pain and improve psychosocial outcomes in youth with sickle cell disease (SCD).\n\nThe main questions it aims to answer are:\n\n* Does MT reduce pain intensity, frequency of pain episodes, and improve health-related quality of life (HRQoL)?\n* Does MT alter immune cell composition and gene expression in inflammatory pathways, as measured by single-cell RNA sequencing (scRNA-seq)?\n\nResearchers will compare participants randomized to music therapy versus a control condition to see if MT produces superior improvements in pain and psychosocial outcomes, and distinct molecular changes.",[65],"Sickle Cell Disease",[67,68,69],"Music therapy","Pain control","Sickle cell disease","NOT_YET_RECRUITING","2026-06-29",{"date":73,"type":46},"2026-07-01",{"date":75,"type":23},"2026-07",{"date":77,"type":23},"2028-04",{"name":52,"class":53},{"id":80,"slug":4,"hasResults":11,"nctId":81,"briefTitle":82,"officialTitle":83,"acronym":4,"eligibilityCriteria":84,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":85,"enrollmentInfo":86,"targetDuration":4,"studyType":24,"phases":88,"briefSummary":89,"conditions":90,"keywords":92,"overallStatus":42,"whyStopped":4,"lastUpdateSubmitDate":96,"lastUpdatePostDateStruct":97,"startDateStruct":99,"completionDateStruct":101,"leadSponsor":103,"locationsCount":104},"100636627","NCT07568145","The PREVENT Resilience Study","PREVENT Study: Promoting Resilience Via Early Neurostimulation After Trauma","Inclusion Criteria:\n\n* Men and women 18-65 years of age. (Assessed via self-reported and medical record-based Date of Birth)\n* Trauma exposed within the last 2 weeks (Endorsement of having experienced an event that could have caused death, serious injury, or sexual violence)\n* High initial symptoms of PTSD related to the index trauma - PCL-5 \\>30 AND meeting for all four DSM-5 clusters.\n* Low symptoms of PTSD related to a previous lifetime trauma - PCL-5\\\u003C31AND does not meet for all four DSM-5 clusters.\n* Participants may be on psychotropic medication, including antidepressants, antipsychotics, benzodiazepines and anticonvulsants, but the dosage of the medication must be stable for at least 6 weeks and not change during the course of the study (Assessed via self-report during the screening phone call).\n* Capable and willing to provide informed consent.\n\nExclusion Criteria:\n\n* Having active suicidal intent or plan, or in the clinician's opinion, is likely to attempt suicide within the next six months. (Assessed via the Patient Health Questionnaire-9 (PHQ-9) during the screening phone call)\n* Lifetime diagnosis of psychotic disorder or bipolar disorder per psychiatric screener. (Assessed via self-report during the screening phone call)\n* Diagnosed with the following conditions: a neurological disorder, including a history of seizures, cerebrovascular disease, primary or secondary tumors in the central nervous system (CNS), stroke, cerebral aneurysm or movement disorder or any lifetime history of loss of consciousness for more than 5 minutes due to head injury (Assessed via self-report during the screening phone call)\n* History of cranial surgery, metallic particles in the eye or head (exclusive of mouth), implanted cardiac pacemaker or any intracardiac lines, implanted neurostimulators, intra-cranial implants (e.g., aneurysm clips, shunts, stimulators, cochlear implants, or electrodes), or implanted medical pumps. (Assessed via self-report during the screening phone call)\n* For women, being pregnant. (Assessed via self-report during the screening phone call, the medical record, and cycling females will undergo a pregnancy test at TMS Day 1)","65 Years",{"count":87,"type":23},50,[26],"PTSD is one of the most universal and severe psychiatric disorders whose incidence continues to rise due to the common exposure to severe trauma in the United States and worldwide. After trauma, a proportion of individuals maintains high symptoms of PTSD and depression, which can persist for years. The early weeks following trauma present a unique opportunity to deliver early interventions that can prevent chronic PTSD and depression from occurring, and the researchers propose a brain-based intervention that will reduce reactivity to threat, an early risk mechanism for chronic PTSD. This study is being done to learn more about whether brain stimulation in the weeks after a trauma can change brain activity that is linked to Post-Traumatic Stress Disorder (PTSD).",[91],"Psychological Trauma",[93,94,95],"Post-Traumatic Stress Disorder","Transcranial Magnetic Stimulation (TMS)","Resilience","2026-06-26",{"date":98,"type":46},"2026-06-30",{"date":100,"type":46},"2026-06-18",{"date":102,"type":23},"2028-03",{"name":52,"class":53},2,{"id":106,"slug":4,"hasResults":11,"nctId":107,"briefTitle":108,"officialTitle":109,"acronym":4,"eligibilityCriteria":110,"healthyVolunteers":11,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":111,"targetDuration":4,"studyType":24,"phases":113,"briefSummary":114,"conditions":115,"keywords":117,"overallStatus":42,"whyStopped":4,"lastUpdateSubmitDate":96,"lastUpdatePostDateStruct":119,"startDateStruct":120,"completionDateStruct":122,"leadSponsor":124,"locationsCount":125},"100475998","NCT05478213","Ventricular Tachycardia Mechanisms","Ventricular Tachycardia Substrate Mechanisms Revealed by Local Repolarization and Conduction Parameters","Inclusion Criteria:\n\n* Diagnosis of ischemic cardiomyopathy\n* Single or dual chamber implantable cardioverter-defibrillator (ICD)\n\nExclusion Criteria:\n\n* Non-Ischemic cardiomyopathy\n* Contraindication to catheter ablation\n* Severe peripheral arterial disease or medical condition that prohibit arterial access\n* Ventricular tachycardia (VT) or sudden cardiac arrest (SCA) within 30 days of acute coronary syndrome or within 90 days of coronary revascularization",{"count":112,"type":23},10,[26],"The purpose of this study is to understand why certain hearts have ventricular arrhythmias and help identify areas of the heart that cause arrhythmias. There is still a significant gap in understanding why ventricular arrhythmias occur. This study will examine the electrical properties of the heart tissue to understand how these arrhythmias occur, and hopefully identify areas that might lead to ventricular arrhythmias. The hope is that studying this might be able to improve outcomes during ventricular tachycardia (VT) ablations.",[116],"Ventricular Tachycardia",[118],"Ventricular tachycardia ablation",{"date":98,"type":46},{"date":121,"type":46},"2022-10-25",{"date":123,"type":23},"2027-05",{"name":52,"class":53},3,{"id":127,"slug":4,"hasResults":11,"nctId":128,"briefTitle":129,"officialTitle":129,"acronym":4,"eligibilityCriteria":130,"healthyVolunteers":17,"sex":18,"minAge":131,"maxAge":4,"enrollmentInfo":132,"targetDuration":4,"studyType":134,"phases":4,"briefSummary":135,"conditions":136,"keywords":4,"overallStatus":42,"whyStopped":4,"lastUpdateSubmitDate":138,"lastUpdatePostDateStruct":139,"startDateStruct":140,"completionDateStruct":142,"leadSponsor":144,"locationsCount":54},"100086092","NCT00378924","Cardiology Biobank Registry","Inclusion Criteria:\n\n1. All hospital and clinic participants aged 18 years and older\n2. Participants with and without active or presumed cardiovascular disease including but not limited to:\n\n   1. Coronary Artery Disease\n   2. Heart Failure and Cardiomyopathies\n   3. Peripheral Vascular Disease\n   4. Valve disease\n   5. Adult Congenital Heart disease\n   6. Electrophysiological Disorders\n3. Any individual aged 18 and above in satisfactory physical health and able to tolerate a blood draw or buccal swab.\n\nExclusion Criteria:\n\n1. Significant Documented Anemia (Hemoglobin \\\u003C8 g\u002FdL)\n2. Blood transfusions within past 3 weeks\n3. Enrollment against doctor recommendation\n4. Participant not able to provide consent including but not limited to:\n\n   1. Intubated and critically unwell participants\n   2. Dementia\n   3. Alzheimer's disease\n   4. Moderate to severe alcohol or drug abuse\n   5. Against religious beliefs (e.g. Jehovah's witness)","20 Years",{"count":133,"type":23},12000,"OBSERVATIONAL","In the present study, investigators intend to establish a large database of cardiovascular patients. More specifically, investigators will create a database of approximately 12,000 cardiac catheterization and heart failure patients from Emory University Hospital, the Emory Clinic, Emory University Hospital Midtown, Grady Memorial Hospital, Atlanta VA Medical Center, Organized\u002FPlanned Community Events in the Atlanta Metropolitan area, held at places of Worship, local Community Centers, shopping Malls, doctor's Offices and Health Clinics and any other miscellaneous locations, e.g. Parks, Leisure centers, Conference centers.\n\nOnce the data has been collected, investigators will run a variety of statistical analyses to which will help us to learn more about the factors that cause various cardiovascular diseases such as coronary heart disease, angina, heart failure, hypertension, and stroke. The statistical analyses will also help us to understand how these diseases can be treated more effectively.\n\nBy collecting a large amount of data on a large number of cardiovascular patients, investigators will be able to analyze, with a great deal of precision, those factors that influence the onset, course, and treatment of cardiovascular disease. The results of these precise analyses can then be used to help optimize clinical efforts to prevent and treat cardiovascular disease.",[137],"Cardiovascular Disease","2026-06-24",{"date":71,"type":46},{"date":141,"type":4},"2003-12",{"date":143,"type":23},"2030-04",{"name":52,"class":53},{"id":146,"slug":4,"hasResults":11,"nctId":147,"briefTitle":148,"officialTitle":148,"acronym":4,"eligibilityCriteria":149,"healthyVolunteers":11,"sex":18,"minAge":150,"maxAge":151,"enrollmentInfo":152,"targetDuration":4,"studyType":24,"phases":154,"briefSummary":156,"conditions":157,"keywords":159,"overallStatus":42,"whyStopped":4,"lastUpdateSubmitDate":161,"lastUpdatePostDateStruct":162,"startDateStruct":163,"completionDateStruct":165,"leadSponsor":167,"locationsCount":168},"100551784","NCT06464588","A Phase 1 Open-Label Study of the Safety of Intravenous Allogeneic Neonatal Mesenchymal Cells (nMSCs) in Young Adult (1A) and Pediatric (1B) Patients With Dilated Cardiomyopathy (DCM)","Inclusion Criteria\n\n* Phase 1A: Age greater than or equal to 16 years and less than 40 years (≥16 years, \\\u003C40 years).\n* Phase 1B: Age greater than or equal to 4 years and less than 16 years (≥4 years, \\\u003C16 years)\n* Subjects must be able to sign their own consent for Phase 1A of the study.\n* Diagnosis of dilated cardiomyopathy (DCM) defined as\n\n  * Any Congenital Cardiac Malformation with systemic ventricular systolic dysfunction; Idiopathic Cardiomyopathy; Familial\u002FInherited and\u002For Genetic Cardiomyopathy; History of Myocarditis; Acquired (Chemotherapy, Iatrogenic, Infection, Rheumatic, Nutritional); Ischemic (e.g. Kawasaki Disease, post-operative); Left ventricular noncompaction; Coronary Artery Disease\n  * Left ventricular ejection fraction less than or equal to 45% documented by two-dimensional echocardiogram or cardiac MRI within the prior six months.\n  * Left ventricular dilation as defined by echocardiography left ventricular and end-diastolic dimension Z score \\> +2.0\n  * Biventricular physiology with systemic left ventricle\n* Must receive guideline directed heart failure as defined by the American Heart Association, American College of Cardiology, and Heart Failure Society of America 118\n* Have been unresponsive or poorly responsive to at least 3 months of maximum guideline directed treatments.\n\nExclusion Criteria\n\n* Listed for heart transplantation (as UNOS status 1A) or hospitalized while waiting for transplant (while on inotropes or with ventricular assist device)\n* Cardiovascular surgery of percutaneous intervention to palliate or correct congenital cardiovascular malformations within 3 months of the screening visit. Patients anticipated to undergo corrective heart surgery during the 12 months after entry into Part 1A\u002F1B.\n* Previous heart transplant recipient\n* Unoperated primary obstructive or severe regurgitant valve (aortic, pulmonary, mitral or tricuspid) disease, or significant systemic ventricular outflow obstruction or aortic arch obstruction anticipated to require surgical or transcatheter intervention within 6 months.\n* Restrictive or hypertrophic cardiomyopathy\n* Cardiogenic shock\n* Currently on extracorporeal membrane oxygenation support\n* Ventricular assist device support\n* Lethal, uncontrollable arrhythmia defined as an arrhythmia resulting in hemodynamic instability requiring need for defibrillation, continuous intravenous anti-arrhythmic medication or mechanical circulatory support\n* Patients with persistent atrial fibrillation requiring specific pharmacotherapy\n* Amyloidosis\n* Ischemic dilated cardiomyopathy\n* Clinical history of malignant neoplasm within 5 years (with the exception of curatively treated basal cell carcinoma, squamous cell carcinoma, or cervical carcinoma)\n* Serious neurologic disorder including loss of vision, stroke, or paralysis\n* High-grade pulmonary embolism requiring interventional catheter procedure or pulmonary hypertension requiring use of pulmonary vasodilators including phosphodiesterase inhibitor or nitric oxide\n* High-grade renal failure \\[eGFR\\\u003C45\\] mL\u002Fmin\u002F1.73 m2 - serum potassium \\>5.3 mmol\u002FL\n* Multiple organ failure\n* Non-cardiac condition that limits life span for \\\u003C1 year\n* Uncontrolled diabetes (HbA1c \\>9%) at screening\n* Active infection (including endocarditis) requiring pharmacotherapy\n* Sepsis\n* Active hemorrhagic disease (e.g., gastrointestinal bleeding, injury)\n* History of cardiac transplantation\n* Immune system-altering medications, or immunosuppressive therapy at the time of enrolment or within the prior 12 weeks\n* Dystrophin-associated cardiomyopathy confirmed by standard cardiomyopathy panel testing\n* Confirmed myocarditis at time of screening\n* Elevated LFTs greater than 2 times upper limit of normal at time of consent\n* Elevated WBC greater than upper limit of normal as defined by local lab at time of consent\n* Presence of HLA antibodies specific for therapeutic study product\n* History of noncompliance, alcohol abuse, recreational drug use, or incarceration within the last year\n* Currently pregnant or breastfeeding\n* Unsafe\u002Funfeasible to enroll due to PI\u002Fdesignee discretion","4 Years","40 Years",{"count":153,"type":23},36,[155],"PHASE1","This is a Phase 1 study to determine the safety and efficacy of allogeneic neonatal mesenchymal stromal cells (nMSCs) for the treatment of Dilated Cardiomyopathy. The purpose of the study is to help doctors and scientists learn if allogeneic neonatal mesenchymal stromal cells (nMSCs) infusions are a safe and effective way to improve cardiac function and left ventricular ejection fraction.",[158],"Dilated Cardiomyopathy",[158,160],"Neonatal Mesenchymal Cells (nMSCs)","2026-06-23",{"date":96,"type":46},{"date":164,"type":46},"2025-07-14",{"date":166,"type":23},"2027-07",{"name":52,"class":53},5,{"id":170,"slug":4,"hasResults":11,"nctId":171,"briefTitle":172,"officialTitle":173,"acronym":4,"eligibilityCriteria":174,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":175,"targetDuration":4,"studyType":24,"phases":177,"briefSummary":178,"conditions":179,"keywords":4,"overallStatus":42,"whyStopped":4,"lastUpdateSubmitDate":181,"lastUpdatePostDateStruct":182,"startDateStruct":183,"completionDateStruct":185,"leadSponsor":187,"locationsCount":54},"100484453","NCT05588245","Trial of Community-based Patient Navigation","A Pragmatic Trial of Integrating Community-based Patient Navigation Into the Continuum of Maternal Care for Black Women in a Safety-Net Health System: Effects on Maternal Health, Health Care, Morbidity, and Mortality","Inclusion Criteria:\n\n* A pregnant woman or individual (inclusive of all gender identities) who is Black and English-speaking (by self-report),\n* ≥18 years of age who is capable of consenting for oneself and who presents for prenatal care with a singleton pregnancy ≤ 20 weeks gestation (confirmed by medical record),\n* covered by Medicaid\n* for whom the AHC-Health Related Social Needs Tool (administered as part of standard clinical care for prenatal patients) identifies ≥1 unmet social needs\n* expectation to receive prenatal care and deliver at Grady and be available through 12-months postpartum to assure opportunity for exposure to the intervention, process, and outcome measure ascertainment.\n\nExclusion Criteria:\n\n* The intent to transfer care to a health system outside of metro Atlanta\n* incarceration, which would interfere with intervention provision and outcome ascertainment\n* adults unable to give consent\n* individuals who are not yet adults\n* prisoners\n* cognitively impaired individuals with impaired decision-making capacity\n* individuals who are not able to clearly understand and speak English (as the PPP-PN intervention is only available in English at this time)",{"count":176,"type":23},540,[26],"This study will test the effectiveness of a community-based patient navigator intervention from mid-pregnancy through 12 month postpartum for a high-risk population of medically underserved women. The RCT will enroll 540 pregnant women before 20 weeks of pregnancy and randomly allocate them into two different study arms from the time of prenatal enrollment through 12 months postpartum. If found to be effective, the community-based patient navigator intervention can be implemented as a standard of care at Grady and other provider practices serving high-risk women to improve maternal health outcomes and reduce racial disparities.",[180],"Pregnancy Related","2026-06-19",{"date":161,"type":46},{"date":184,"type":46},"2024-01-25",{"date":186,"type":23},"2027-06",{"name":52,"class":53},{"id":189,"slug":4,"hasResults":11,"nctId":190,"briefTitle":191,"officialTitle":191,"acronym":4,"eligibilityCriteria":192,"healthyVolunteers":11,"sex":18,"minAge":19,"maxAge":193,"enrollmentInfo":194,"targetDuration":4,"studyType":24,"phases":196,"briefSummary":197,"conditions":198,"keywords":201,"overallStatus":70,"whyStopped":4,"lastUpdateSubmitDate":203,"lastUpdatePostDateStruct":204,"startDateStruct":205,"completionDateStruct":206,"leadSponsor":208,"locationsCount":104},"100644396","NCT07663292","Neuroplastic Changes Due to an Exercise Intervention That Aid in Lower Limb Recovery After Subcortical Stroke","Inclusion Criteria:\n\n* chronic left or right subcortical stroke as defined by 6 months or more after a cardiovascular accident\n* lower extremity motor impairment due to stroke that causes a walking speed of less than 0.6 m\u002Fs during a 10m walk,\n* age 18-80 years old, and\n* Screen pass of the Stress test or Physician sign-off from the participant's health care team that they are cleared for a 12 week exercise intervention\n\nExclusion Criteria:\n\n* MRI contraindications, including implanted cardiac pacemakers and severe claustrophobia\n* any neurodegenerative condition other than stroke that may lead to lower extremity impairment\n* visual or auditory impairment that may hinder study procedures, and\n* any medical condition that would preclude from participation in a physical exercise intervention program.","80 Years",{"count":195,"type":23},55,[26],"This study aims to develop imaging-based biomarkers to assess which chronic stroke participant with lower extremity disability may respond or resist high intensity interval training (HIIT).\n\nPrevious research suggests that physical exercise training is safe and could help improve the walking speed of non-ambulatory stroke survivors. However, inter-individual variability in response to exercise is extraordinarily high regardless of adherence, and predictors of response remain elusive.\n\nChronic stroke survivors with lower limb disability resulting in slow walking speeds will participate in 12 weeks of cycling exercise at Emory University under the guidance of a physical exercise instructor, 3 days a week, for 25-60 minutes. During some of the exercise sessions, the investigators will collect blood lactate with a finger prick. Brain scans with an MRI before and after the 12 weeks of exercise will be done; motor function tests that include walking, sitting down, standing up, and turning around will be collected. Participants' memory and thinking will be assessed, and participants will fill out questionnaires about their health before and after their stroke, and well as questions about their diet.\n\nThe participation will last between 14-16 weeks (up to 42 study visits).",[199,200],"Subcortical Lesions","Stroke",[202],"High intensity interval training","2026-06-17",{"date":161,"type":46},{"date":75,"type":23},{"date":207,"type":23},"2027-03",{"name":52,"class":53},{"id":210,"slug":4,"hasResults":11,"nctId":211,"briefTitle":212,"officialTitle":212,"acronym":4,"eligibilityCriteria":213,"healthyVolunteers":11,"sex":18,"minAge":214,"maxAge":215,"enrollmentInfo":216,"targetDuration":4,"studyType":24,"phases":218,"briefSummary":219,"conditions":220,"keywords":222,"overallStatus":42,"whyStopped":4,"lastUpdateSubmitDate":224,"lastUpdatePostDateStruct":225,"startDateStruct":226,"completionDateStruct":228,"leadSponsor":230,"locationsCount":125},"100626446","NCT07435740","Parent-Mediated Telehealth Intervention for Insomnia in Young Autistic Children","Inclusion Criteria:\n\n* Age \\>3 to 7 years 11 months\n* Clinical diagnosis of ASD supported by the Autism Diagnostic Interview Revised (ADI-R)\n* Score of 30 or more on the Parent-Rated Insomnia Scale - ASD (PAIRS) and the Clinical Global Impression Severity (CGI-S) score of Moderate or greater (a score of 4 or more)\n* Medication and supplement free or on stable medication or supplements (no changes in the past 6 weeks and no planned changes for 10 weeks of the randomized trial)\n* Parental proficiency in spoken and written English language. Study materials and many of the study measures are only available in English\n\nExclusion Criteria:\n\n* Children with a history of serious medical condition or known medical cause insomnia (e.g., nocturnal seizures, unresolved gastrointestinal problems such as reflux or constipation)\n* Children with a psychiatric disorder or serious behavioral problem requiring a different treatment\n* Children with known sleep apnea, restless leg syndrome, or periodic limb movements during sleep, or a circadian-based sleep disorder (e.g., delayed or advanced sleep phase syndrome)\n* Children of non-English language speaking caregivers will be excluded because study intervention materials and many of the study measures are only available in English","3 Years","7 Years",{"count":217,"type":23},130,[26],"This study will evaluate the efficacy of a structured parent-mediated behavioral intervention called Sleep Parent Treatment (SPT) for insomnia in autistic children ages 3 to 7 years 11 months, compared to another behavioral intervention called Sleep Parent Education (SPE). Eligible children will be randomly assigned to either the SPT or SPE intervention for 10 weeks.",[221],"Insomnia",[223],"autism","2026-06-16",{"date":100,"type":46},{"date":227,"type":46},"2026-06-05",{"date":229,"type":23},"2031-01",{"name":52,"class":53},{"id":232,"slug":4,"hasResults":11,"nctId":233,"briefTitle":234,"officialTitle":235,"acronym":4,"eligibilityCriteria":236,"healthyVolunteers":11,"sex":18,"minAge":237,"maxAge":238,"enrollmentInfo":239,"targetDuration":4,"studyType":24,"phases":241,"briefSummary":243,"conditions":244,"keywords":4,"overallStatus":42,"whyStopped":4,"lastUpdateSubmitDate":224,"lastUpdatePostDateStruct":247,"startDateStruct":248,"completionDateStruct":250,"leadSponsor":251,"locationsCount":54},"100610373","NCT07226739","Comprehensive Toileting Program","Comprehensive Toileting Programming: Enuresis Treatment to a Randomized Clinical Trial of a Caregiver-Mediated Multidisciplinary Intervention for Encopresis","Inclusion Criteria\n\n* Age 5 to 12\n* Diagnosis of an intellectual or developmental delay (excluding individuals with ADHD alone)\n* Encopresis (more than 1 incontinent BM a week)\n* Required for pre-randomization phase only: Enuresis (\\> 1 incontinent urination per day when on a consistent toileting sit schedule)\n* At least one caregiver who speaks and understands English\n\nExclusion Criteria:\n\n* Unresolved medical condition that would impede toilet training (e.g., interference with sphincter control, short gut syndrome, urinary tract or gastrointestinal infection, unexplained diarrhea, recent intestinal surgery, inflammatory bowel disease)\n* Failed intensive toileting treatment in the past 2 yrs with protocols akin to study\n* Current serious behavioral or psychiatric disorder that requires another treatment\n* Current or planned other intervention (behavioral or medical) for incontinence","5 Years","12 Years",{"count":240,"type":23},150,[242],"PHASE4","The current study aims to monitor fecal continence after autistic youth complete enuresis treatment and for individuals who continue to experience encopresis after acquiring urine continence, evaluate a caregiver-mediated version of a Multidisciplinary Intervention for Encopresis (CM-MIE) delivered via telehealth to determine efficacy in a randomized clinical trial.",[245,246],"Encopresis","ASD",{"date":100,"type":46},{"date":249,"type":46},"2026-06-01",{"date":229,"type":23},{"name":52,"class":53},{"id":253,"slug":4,"hasResults":11,"nctId":254,"briefTitle":255,"officialTitle":255,"acronym":256,"eligibilityCriteria":257,"healthyVolunteers":11,"sex":18,"minAge":150,"maxAge":238,"enrollmentInfo":258,"targetDuration":4,"studyType":24,"phases":259,"briefSummary":260,"conditions":261,"keywords":263,"overallStatus":42,"whyStopped":4,"lastUpdateSubmitDate":224,"lastUpdatePostDateStruct":268,"startDateStruct":269,"completionDateStruct":271,"leadSponsor":273,"locationsCount":54},"100607863","NCT07194083","Effectiveness- Implementation Trial of the Function-Based Elopement Treatment","(FBET)","Inclusion Criteria:\n\nChild participant:\n\n* Boys and girls ages \\> 4 to \\\u003C 12 years\n* Autism Spectrum Disorder (ASD) diagnosis by history\n* Presence of elopement as an important caregiver concern - elopement occurring regularly for at least 3 months.\n* At least one primary caregiver can speak and understand English.\n\nExclusion Criteria:\n\n• Non-English speaking participants",{"count":87,"type":23},[26],"The goal of this clinical trial is to test whether the Function-Based Elopement Treatment (FBET) can reduce elopement in children aged 4-12 with autism spectrum disorder (ASD), and to assess its feasibility in community-based Applied Behavior Analysis (ABA) clinics. Researchers will evaluate FBET in a single-arm open-label trial in one clinic, followed by a comparison of FBET to treatment as usual (TAU) across at least six ABA clinics to evaluate effectiveness and implementation.\n\nThe main questions it aims to answer are:\n\n* Is it feasible to use FBET in community-based ABA clinics?\n* Does FBET reduce elopement?\n* Does FBET lead to greater clinical improvement?\n\nParticipants will:\n\n* Receive 12 sessions of FBET over 20 weeks with trained BCBAs or receive treatment as usual\n* Complete caregiver assessments at baseline and endpoint\n* Engage in caregiver training and practice treatment between appointments",[262],"Autism Spectrum Disorder",[264,262,265,266,267],"Function Based Elopement Treatment","Applied Behavior Analysis","Elopement","Functional Analysis",{"date":100,"type":46},{"date":270,"type":46},"2026-03-30",{"date":272,"type":23},"2028-10",{"name":52,"class":53},{"id":275,"slug":4,"hasResults":11,"nctId":276,"briefTitle":277,"officialTitle":277,"acronym":4,"eligibilityCriteria":278,"healthyVolunteers":11,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":279,"targetDuration":237,"studyType":134,"phases":4,"briefSummary":281,"conditions":282,"keywords":284,"overallStatus":42,"whyStopped":4,"lastUpdateSubmitDate":288,"lastUpdatePostDateStruct":289,"startDateStruct":291,"completionDateStruct":293,"leadSponsor":295,"locationsCount":296},"100635993","NCT07559903","ANDREAS Registry (Assessment of Novel Drug-coated Balloon Revascularization: Effectiveness, Angiographic Outcomes, and Safety)","Inclusion Criteria:\n\n* All adult patients (≥ 18 years of age) undergoing PCI for de novo CAD using DCB\n\nExclusion Criteria:\n\n* Patients under the age of 18; PCI procedures without the utilization of DCB; PCI procedures for non de novo lesions",{"count":280,"type":23},5000,"The primary objective of this protocol is to develop a comprehensive, multicenter international prospective registry to capture long-term clinical outcomes for adult patients undergoing percutaneous coronary intervention (PCI) with drug-coated balloons (DCB) for de novo coronary artery disease.",[283],"Coronary Artery Disease",[285,286,287],"Drug coated balloon","Percutaneous coronary intervention","Target lesion failure","2026-06-12",{"date":290,"type":46},"2026-06-15",{"date":292,"type":23},"2026-06",{"date":294,"type":23},"2031-05",{"name":52,"class":53},19,{"id":298,"slug":4,"hasResults":11,"nctId":299,"briefTitle":300,"officialTitle":300,"acronym":4,"eligibilityCriteria":301,"healthyVolunteers":11,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":302,"targetDuration":4,"studyType":24,"phases":304,"briefSummary":305,"conditions":306,"keywords":308,"overallStatus":42,"whyStopped":4,"lastUpdateSubmitDate":288,"lastUpdatePostDateStruct":311,"startDateStruct":312,"completionDateStruct":314,"leadSponsor":316,"locationsCount":104},"100569866","NCT06699810","Modeling Ketosis-Prone Diabetes Remission Via Diverse Mechanisms of Glucotoxicity","Inclusion Criteria:\n\n* Provide informed consent\n* Have a BMI ≥ 28 kg\u002Fm2\n* Be of African American ancestry\n* Meet diagnostic criteria for DKA. Diagnostic criteria for DKA will include a plasma glucose \\> 250 mg\u002Fdl, a venous pH \\\u003C 7.30, a serum bicarbonate \\\u003C 18 mmol\u002Fl, and serum ketones (beta-hydroxy butyrate) \\> 1.5 mmol\u002FL.\n\nExclusion Criteria:\n\n* Significant medical or surgical illness including but not limited to myocardial ischemia, congestive heart failure, chronic peripheral venous insufficiency, chronic renal insufficiency, liver insufficiency (serum transaminases 3 times the upper limit of normal) and acute or chronic infectious processes\n* Have recognized uncontrolled endocrine disorders such as hypercortisolism, acromegaly, or hyperthyroidism\n* Anemia (hemoglobin \\\u003C 12.5 g\u002FdL for men, \\\u003C11.5 gm\u002FdL for women), bleeding disorders, or abnormalities in coagulation studies\n* Pregnant\n* Diagnosis of diabetes \\> 90 days before the presentation of DKA\n* Unable to give consent",{"count":303,"type":23},12,[242],"The goal of this study is to quantify day-to-day changes in blood glucose during treatment towards remission in ketosis-prone diabetes (KPDM) and describe them using a mathematical model of KPDM pathogenesis and remission.",[307],"Ketosis Prone Diabetes",[309,310],"diabetic ketoacidosis","type 2 diabetes",{"date":290,"type":46},{"date":313,"type":46},"2025-01-23",{"date":315,"type":23},"2027-01",{"name":52,"class":53},{"id":318,"slug":4,"hasResults":11,"nctId":319,"briefTitle":320,"officialTitle":321,"acronym":4,"eligibilityCriteria":322,"healthyVolunteers":11,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":323,"targetDuration":4,"studyType":24,"phases":325,"briefSummary":326,"conditions":327,"keywords":338,"overallStatus":42,"whyStopped":4,"lastUpdateSubmitDate":288,"lastUpdatePostDateStruct":351,"startDateStruct":352,"completionDateStruct":354,"leadSponsor":356,"locationsCount":357},"100509219","NCT05910580","Improving Alcohol and Substance Use Care Access, Outcome, Equity During the Reproductive Years","Improving Alcohol and Substance Use Care Access, Outcomes, and Equity During the Reproductive Years: A Type 1 Hybrid Trial in Family Planning Clinics","Inclusion Criteria:\n\n* Over the age of 18 years\n* U.S. residing\n* Have internet access (own a computer or smart phone)\n* Screen positive to one or more risky alcohol and substance use behaviors as determined by our standardized abbreviated instruments\n\nExclusion Criteria:\n\n* Not capable of communicating (reading, speaking, writing) in English or Spanish",{"count":324,"type":23},400,[26],"The goal of this clinical trial is to test the effectiveness of evidence-based Screening, Brief Intervention, and Referral to Treatment (SBIRT) among adult patients who screen positive to one or more risky alcohol or substance use behaviors while seeking care at a sexual and reproductive health (SRH) clinic.\n\nThe main questions it aims to answer are:\n\n* Does SBIRT impact patients' alcohol and substance use, SRH, mental health, physical health, quality of life, and wellbeing?\n* Does SBIRT effectiveness differ by ethnicity, socioeconomic status, age, gender, and urbanicity?\n* Does SBIRT effectiveness differ by delivery mode (in-person vs. telemedicine)?\n\nParticipants will receive in-person and telemedicine SBIRT, or usual care. Participants will complete surveys at interviews at baseline, 30 days, and 3 months.\n\nResearchers will compare patients who received SBIRT to patients who receive usual care to see if patients who receive the SBIRT intervention have a greater reduction in negative outcomes as compared to those who receive usual care. In this setting, usual care consists of basic quantity and frequency questions asked inconsistently as part of the admission process and varying by provider, with no standardized approach to screening, treatment, follow-up, or referral.",[328,329,330,331,332,333,334,335,336,337],"Alcohol-Related Disorders","Substance-Related Disorders","Mental Health","Reproductive Health","Sexual Health","Sexually Transmitted Diseases","Contraception","Maternal Health","Pregnancy","Women's Health",[339,340,341,342,343,344,345,346,347,348,349,350],"Implementation Science","Mass Screening","Motivational Interviewing","Referral and Consultation","Quality of Health Care","Early Medical Intervention","Family Planning Services","Primary Health Care","Reproductive Health Services","Telemedicine","Preconception Care","Young Adult",{"date":290,"type":46},{"date":353,"type":46},"2025-07-03",{"date":355,"type":23},"2027-05-31",{"name":52,"class":53},4,{"id":359,"slug":4,"hasResults":11,"nctId":360,"briefTitle":361,"officialTitle":362,"acronym":4,"eligibilityCriteria":363,"healthyVolunteers":11,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":364,"targetDuration":4,"studyType":24,"phases":366,"briefSummary":367,"conditions":368,"keywords":4,"overallStatus":42,"whyStopped":4,"lastUpdateSubmitDate":288,"lastUpdatePostDateStruct":370,"startDateStruct":371,"completionDateStruct":373,"leadSponsor":375,"locationsCount":104},"100399591","NCT04483206","Personalized Autologous Transplant for Multiple Myeloma","Phase 1 of Exposure Targeted Melphalan Dosing","Inclusion Criteria:\n\n* Patient must have the clinical diagnosis of a plasma cell neoplasm requiring treatment per the treating physician using the International Myeloma Working Group (IMWG) and World Health Organization (WHO) criteria as guidelines. This can include extraosseous plasmacytoma, monoclonal immunoglobulin deposition disease, and heavy-chain diseases as these diagnoses, while rare, can be treated in part with autologous transplant\n* If enrolling in phase A of this protocol, the patient\n\n  * must have received 2+ lines of therapy as defined by the IMWG; and\n  * Must have estimated glomerular filtration rate (eGFR) by Cockcroft-Gault \\> 40 mL\u002Fmin; and\n  * Be eligible and appropriate per the treating physician to receive 200 mg\u002Fm\\^2\n\n    * If enrolling in phase B of the protocol, the transplant must be part of first line therapy to provide some level of homogeneity for toxicity assessment and preliminary efficacy\n* Absolute neutrophil count (ANC) \\>= 1000\u002FuL\n* Platelet count \\>= 100,000\n* Total bilirubin \\\u003C 1.5 x institutional upper limit of normal (unless the patient has an established diagnosis of Gilbert's in which case total bilirubin \\\u003C 3 mg\u002FdL)\n* Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) \\\u003C 3 x the institutional upper limit of normal\n* Left ventricular ejection fraction \\>= 45%\n* Diffusion capacity of the lung for carbon monoxide (DLCO), forced expiratory volume in 1 second (FEV1), and forced vital capacity (FVC) \\> 50% of predicted value (corrected for hemoglobin)\n* Eastern Cooperative Oncology Group (ECOG) performance status =\\\u003C 2 (Karnofsky \\>= 60%) is required for eligibility. Those patients with lower performance status based solely on bone pain secondary to multiple myeloma are eligible\n* Females of childbearing potential (FCBP) must have a negative serum or urine pregnancy test prior to starting therapy. The effects of protocol therapy on the developing human fetus are unknown. For this reason, FCBP and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation. Should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately. Men treated or enrolled on this protocol must also agree to use adequate contraception prior to the study, for the duration of study participation, and 3 months after completion of protocol therapy administration. Female of childbearing potential (FCBP) is a sexually mature woman who: 1) has not undergone a hysterectomy or bilateral oophorectomy; or 2) has not been naturally postmenopausal for at least 24 consecutive months (i.e., has had menses at any time in the preceding 24 consecutive months)\n* The patient must be willing to comply with fertility requirements\n* Ability to understand and the willingness to sign a written informed consent document\n* Patients with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen are eligible for this trial\n\nExclusion Criteria:\n\n* Patients known to meet criteria for progressive disease or clinical relapse between screening and planned melphalan infusion day -3\n* Subject has any of the following cardiac abnormalities\n\n  * History of clinically significant cardiovascular disease with New York Heart Association class III or IV congestive heart failure or\n  * Severe non-ischemic cardiomyopathy or\n  * Myocardial infarction within the previous 6 months prior to starting study treatment\n  * Unstable or poorly controlled angina\n  * Uncontrolled severe hypertension\n  * Clinically\u002Fhemodynamically significant arrythmias\n  * Severe uncontrolled cardiac arrhythmias (grade 3 or higher) or\n  * Clinically significant electrocardiogram (ECG) abnormalities includingcorrected QT interval (QTc) \\> 480 msec\n* Human immunodeficiency virus (HIV) positive EXCEPT if the patient meets all the following: CD4 \\> 350 cells\u002Fmm\\^3, undetectable viral load, maintained on modern therapeutic regimen utilizing non CYP interacting agents (e.g. excluding ritonavir), and no untreated acquired immune deficiency syndrome defining opportunistic infections.\n* Seropositive for hepatitis B surface antigen \\[HBsAg\\]) EXCEPT subjects with resolved infection (ie, subjects who are positive for antibodies to hepatitis B core antigen \\[antiHBc\\] and\u002For antibodies to hepatitis B surface antigen \\[antiHBs\\]) must be screened using real-time polymerase chain reaction (PCR) measurement of hepatitis B virus (HBV) DNA levels. Those who are PCR positive will be excluded. Subjects with serologic findings suggestive of HBV vaccination (antiHBs positivity as the only serologic marker) AND a known history of prior HBV vaccination, do not need to be tested for HBV DNA by PCR\n* Seropositive for hepatitis C except in the setting of a sustained virologic response \\[SVR\\], defined as without viremia for at least 12 weeks after completion of antiviral therapy\n* Polyneuropathy, organomegaly, endocrinopathy, monoclonal gammopathy, and skin change (POEMS) syndrome, amyloid light-chain (AL) amyloidosis, and Waldenstrom macroglobulinemia\n* Concurrent medical condition or disease (eg, active systemic infection) that is likely to interfere with study procedures or results, or that in the opinion of the investigator would constitute a hazard for participating in this study\n* Known or suspected of not being able to comply with the study protocol (eg, because of alcoholism, drug dependency, or psychological disorder) or the subject has any condition for which, in the opinion of the investigator, participation would not be in the best interest of the subject (eg, compromise their well-being) or that could prevent, limit, or confound the protocol-specified assessments\n* Pregnant women are excluded from this study because protocol therapy has the potential for teratogenic or abortifacient effects. Because there is an unknown but potential risk for adverse events in nursing infants secondary to protocol treatment of the mother, breastfeeding should be discontinued",{"count":365,"type":23},90,[155],"This phase I trial studies the best dose and side effects of mephalan in treating patients with multiple myeloma who are undergoing stem cell transplant. Chemotherapy drugs, such as mephalan, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. This trial uses a new method of dosing that is based on analysis of each individual's blood levels of melphalan after receiving a part of the dose, termed pharmacokinetic analysis. This may help to learn more about how to dose melphalan correctly and which patients are likely to benefit from a personalized dose.",[369],"Multiple Myeloma",{"date":290,"type":46},{"date":372,"type":46},"2021-05-20",{"date":374,"type":23},"2027-12-31",{"name":52,"class":53},{"id":377,"slug":4,"hasResults":11,"nctId":378,"briefTitle":379,"officialTitle":380,"acronym":381,"eligibilityCriteria":382,"healthyVolunteers":11,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":383,"targetDuration":4,"studyType":134,"phases":4,"briefSummary":385,"conditions":386,"keywords":388,"overallStatus":70,"whyStopped":4,"lastUpdateSubmitDate":392,"lastUpdatePostDateStruct":393,"startDateStruct":394,"completionDateStruct":395,"leadSponsor":397,"locationsCount":54},"100642204","NCT07651631","Rapid Evacuation and Access of Cerebral Hemorrhage Registry","A Prospective, Multicenter, Global Registry Evaluating Minimally Invasive Surgery for the Treatment of Acute Spontaneous Supratentorial Intracerebral Hemorrhage.","REACH","Inclusion Criteria:\n\n* Head CT demonstrating an acute, spontaneous, intracerebral hemorrhage\n* Hemorrhage volume ≥ 20 mLs\n* Minimally invasive surgical intervention performed within 7 days of hemorrhage\n\nExclusion Criteria:\n\n* Ruptured aneurysm, arteriovenous malformation (AVM), vascular anomaly, moyamoya disease, venous sinus thrombosis, mass or tumor, hemorrhagic conversion of an ischemic infarct, recurrence of a recent ICH (\\\u003C1 year), as diagnosed with radiographic imaging\n* Infratentorial intraparenchymal hemorrhage, including midbrain, pontine, or cerebellum\n* Initial hospital arrival ≥ 24 hours after the onset of stroke symptoms\n* Last known normal is unknown\n* Historical Modified Rankin Score \\> 4\n* Known life-expectancy of less than 1 year prior to ICH\n* DNR or comfort measures only\n* Known pregnancy in female subjects\n* Inability or unwillingness of subject or legal guardian\u002Frepresentative to give written informed consent within 7 days of initial hospital arrival\n* Inability to meet follow up requiremen",{"count":384,"type":23},2500,"The goal of this observational study is to quantify the real-world effect of minimally invasive surgery (MIS) in patients with acute spontaneous supratentorial intracerebral hemorrhage.",[387],"Intracerebral Hemorrhage",[387,389,390,391],"ICH is the basal ganglia","modified Rankin Scale","Arteriovenous Malformation","2026-06-11",{"date":224,"type":46},{"date":292,"type":23},{"date":396,"type":23},"2033-06",{"name":52,"class":53},{"id":399,"slug":4,"hasResults":11,"nctId":400,"briefTitle":401,"officialTitle":402,"acronym":4,"eligibilityCriteria":403,"healthyVolunteers":17,"sex":18,"minAge":404,"maxAge":405,"enrollmentInfo":406,"targetDuration":4,"studyType":24,"phases":408,"briefSummary":409,"conditions":410,"keywords":412,"overallStatus":42,"whyStopped":4,"lastUpdateSubmitDate":416,"lastUpdatePostDateStruct":417,"startDateStruct":418,"completionDateStruct":419,"leadSponsor":420,"locationsCount":104},"100633144","NCT07522866","Thrive With Type 1 Diabetes 2026","Intervention to Thrive With Type 1 Diabetes 2026","Inclusion Criteria:\n\n* Aged 31 to 75 years\n* Type 1 Diabetes for at least 1 year\n* One or more sleep health dimensions are out of range\n\nExclusion Criteria:\n\n* Non-English speaking\n* Recent night shift work or transmeridian travel\n* Life-limiting illness","31 Years","75 Years",{"count":407,"type":23},48,[26],"This study aims to learn whether a cognitive behavioral intervention can improve lifestyle and glucose targets for adults with type 1 diabetes.",[411],"Type1diabetes",[413,414,415],"Glycemia","A1C","Sleep","2026-06-09",{"date":392,"type":46},{"date":75,"type":23},{"date":77,"type":23},{"name":52,"class":53},{"id":422,"slug":4,"hasResults":11,"nctId":423,"briefTitle":424,"officialTitle":425,"acronym":4,"eligibilityCriteria":426,"healthyVolunteers":11,"sex":18,"minAge":427,"maxAge":428,"enrollmentInfo":429,"targetDuration":4,"studyType":24,"phases":430,"briefSummary":431,"conditions":432,"keywords":434,"overallStatus":70,"whyStopped":4,"lastUpdateSubmitDate":438,"lastUpdatePostDateStruct":439,"startDateStruct":441,"completionDateStruct":443,"leadSponsor":445,"locationsCount":54},"100600239","NCT07094906","Handgrip Exercise Training and CKD","Neural and Vascular Modulation With Isometric Handgrip Training in Chronic Kidney Disease","Inclusion Criteria:\n\n* Patients with CKD (Stages IIIa and IV),\n* Ages 45-85 years who do not regularly exercise (defined as exercising less than 20 minutes twice per week), willing and able to cooperate with the protocol.\n* CKD Stages III and IV will be defined as reduction in estimated glomerular filtration rate (eGFR) to 15-59 cc\u002Fminute as calculated by the modified CKD-EPI equations.\n* Patients with CKD must have stable renal function (no greater than a 20% reduction in eGFR over the prior 3 months).\n\nExclusion Criteria:\n\n* Severe CKD (eGFR\\\u003C15 cc\u002Fminute)\n* Metabolic alkalosis (serum bicarbonate \\> 28 meq\u002FL)\n* Ongoing drug or alcohol abuse\n* Diabetic neuropathy\n* Any serious systemic disease that might influence survival\n* Severe anemia with hgb level \\\u003C10 g\u002FdL\n* Clinical evidence of congestive heart failure or ejection fraction below 35%, symptomatic heart disease determined by prior electrocardiogram, stress test, and\u002For history, treatment with central alpha agonists (clonidine)\n* Uncontrolled hypertension with BP greater than 170\u002F100 mm Hg\n* Low blood pressure with BP less than 100\u002F50\n* Pregnancy or plans to become pregnant\n* Current treatment with MAO inhibitors\n* Inability to perform handgrip exercise","45 Years","85 Years",{"count":87,"type":23},[26],"The purpose of this study is to find out if regular handgrip exercise performed at home can improve blood pressure at rest and during exercise in patients with chronic kidney disease (CKD).\n\nThis study is also intended to understand what causes an increase in blood pressure at rest and during exercise (i.e., increased adrenaline levels, or decreased ability of blood vessels to dilate). Patients with CKD will be recruited from primary care, Nephrology and other subspecialty Clinics throughout the Emory Healthcare System. Participants will attend 4 visits of 2-3 hours and 3 visits of 1-2 hours. The home exercise training will last for 8 weeks.",[433],"Chronic Kidney Diseases",[435,436,437],"Handgrip","Isometric handgrip exercise training (IHT)","Blood pressure variability","2026-06-08",{"date":440,"type":46},"2026-06-10",{"date":442,"type":23},"2026-09",{"date":444,"type":23},"2027-12",{"name":52,"class":53},{"id":447,"slug":4,"hasResults":11,"nctId":448,"briefTitle":449,"officialTitle":450,"acronym":4,"eligibilityCriteria":451,"healthyVolunteers":11,"sex":18,"minAge":452,"maxAge":453,"enrollmentInfo":454,"targetDuration":4,"studyType":24,"phases":456,"briefSummary":457,"conditions":458,"keywords":460,"overallStatus":42,"whyStopped":4,"lastUpdateSubmitDate":438,"lastUpdatePostDateStruct":464,"startDateStruct":465,"completionDateStruct":467,"leadSponsor":469,"locationsCount":54},"100471516","NCT05419895","Early Diagnostic Response Model (EDRM)","Early Diagnostic Response Model (EDRM): Evaluating an Early Screening to Evaluation Pilot Protocol for Children Identified as High Risk for Autism in Early Intervention Health Districts","Inclusion Criteria:\n\n* All families of children between the ages of 16-30 months of age who scored ≥8 on the MCHAT-R and whose BCW provider refers the child to our clinic by 33 months of age will be a possible participant. Evaluations will be done by 36 months of age.\n* Referring BCW provider must be one of the participating BCW health districts in this pilot study.\n* Parent\u002FGuardian needs to have basic English proficiency\n* Parent\u002FGuardian needs to have internet access\n* Child must have exposure to English either at home or in out-of-home care (e.g., childcare setting).\n* Documentation of M-CHAT-R High-Risk failed score (≥ 8) must be documented in referral.\n\nExclusion Criteria:\n\n* Families making self-referrals to the EAC or referrals outside of the targeted BCW districts will be excluded from recruitment for this study.\n* Children above the age of 33 months at the time of the referral will be excluded as the current EDRM protocol has not been developed in this phase of piloting for individuals over this age.\n* Non-English speakers will be excluded from participation due to the current protocol not being applicable to their needs as well as a high correlation between verbal language abilities and social communication and social interaction (SCI) abilities as part of the DSM-5-TR autism criteria.","16 Months","36 Months",{"count":455,"type":23},300,[26],"Babies Can't Wait (BCW) in Georgia will be referring families with children seeking an autism spectrum disorder (autism) diagnosis at the Emory Autism Center's (EAC) Child Screening and Assessment Clinic.The objective of this study is to develop, pilot, and evaluate a diagnostic protocol for children identified at high risk for autism in the BCW early intervention program screening (part of a public health service). This program evaluation will be using pre- and post-data and data collected through the process to evaluate the effectiveness of the EDRM pilot.",[262,459],"Autism",[459,461,462,463],"Early Intervention","Telehealth","Assessment",{"date":440,"type":46},{"date":466,"type":46},"2022-06-16",{"date":468,"type":23},"2028-07",{"name":52,"class":53},{"id":471,"slug":4,"hasResults":11,"nctId":472,"briefTitle":473,"officialTitle":473,"acronym":4,"eligibilityCriteria":474,"healthyVolunteers":17,"sex":475,"minAge":19,"maxAge":476,"enrollmentInfo":477,"targetDuration":4,"studyType":24,"phases":479,"briefSummary":480,"conditions":481,"keywords":489,"overallStatus":42,"whyStopped":4,"lastUpdateSubmitDate":496,"lastUpdatePostDateStruct":497,"startDateStruct":498,"completionDateStruct":500,"leadSponsor":501,"locationsCount":54},"100601479","NCT07111026","Sisters for Heart Health: A Community Health Worker Initiative for Improving Heart Health in Farmworker Women","Inclusion Criteria:\n\n* Self-identified female employed as a farmworker;\n* Fluent in Spanish or English verbal literacy\n* Planning to be in the geographic area for a minimum of 6 months.\n\nExclusion Criteria:\n\n* Cognitive or psychological impairment precluding informed consent and\u002For active participation in the study due to substance use, neurologic, or other disorder\n* Pregnant or breastfeeding.","FEMALE","50 Years",{"count":478,"type":23},269,[26],"The goal of this hybrid Type 1 effectiveness-implementation trial is to test the extent to which a peer support and community resource navigation intervention improves psychological well-being, addresses non-biologic drivers of health (access to healthcare, supportive services, nutrition, housing stability, transportation, chronic stress, social support), and thus reduces cardiometabolic risk among rural, low-income farmworker women aged 18-50 years. The main questions it aims to answer are:\n\n* If and to what extent does the intervention reduce stress, social isolation, and psychological distress by improving social support and access to needed resources?\n* If and to what extent does the intervention improve cardiometabolic health, measured by the American Heart Association's Life's Essential 8 (LE8) score?\n\nResearchers will compare the CHW-led Sisters for Heart Health intervention to a Basic intervention (LE8 assessment and resource information) to assess the effect of peer support and community resource navigation on heart health outcomes.",[482,483,484,485,486,487,488],"Occupational Stress","Gender Related Stress","Social Isolation","Hypertension","Pre Diabetes","Diabetes","Obesity",[490,491,492,493,494,495],"occupational stress","gender related stress","social isolation","psychological stress","cardiometabolic health","non biological drivers of health","2026-06-04",{"date":438,"type":46},{"date":499,"type":46},"2025-09-16",{"date":50,"type":23},{"name":52,"class":53},{"id":503,"slug":4,"hasResults":11,"nctId":504,"briefTitle":505,"officialTitle":505,"acronym":4,"eligibilityCriteria":506,"healthyVolunteers":11,"sex":18,"minAge":85,"maxAge":4,"enrollmentInfo":507,"targetDuration":4,"studyType":24,"phases":509,"briefSummary":510,"conditions":511,"keywords":514,"overallStatus":42,"whyStopped":4,"lastUpdateSubmitDate":516,"lastUpdatePostDateStruct":517,"startDateStruct":518,"completionDateStruct":519,"leadSponsor":521,"locationsCount":54},"100629415","NCT07474376","Diabetes Multimorbidity Typology, Trajectory, and Feasibility of an Audio Diary Mobile Application to Support Self-management","Inclusion Criteria:\n\n* Diagnosed type 1 or 2 diabetes and at least one comorbidity (eg, obesity, HIV, heart failure, polycystic ovary syndrome, obstructive sleep apnea, and prediabetes with and without hypertension)\n* Being able to fill in the Redcap surveys, and install and use the audio diary app.\n\nExclusion Criteria:\n\n•Those who cannot use (e.g., no mobile phone, incompatible system), read, type, speak, or understand English in Redcap or the audio diary mobile app.",{"count":508,"type":23},30,[26],"The goal of this clinical trial is to evaluate whether an audio diary mobile application (Fabla-diabetesMM) is feasible to use and may support self-management in older adults with type 1 or 2 diabetes and multimorbidity.\n\nThe main questions it aims to answer are:\n\n* Is it feasible to adapt and implement the Fabla-diabetesMM audio diary mobile app among 30 older adults with diabetes and multimorbidity\n* Does the use of the audio diary mobile app affect self-management outcomes",[512,513],"Diabetes Mellitus, Type 2","Diabetes Mellitus, Type 1",[515],"Diabetes self management","2026-06-03",{"date":496,"type":46},{"date":292,"type":23},{"date":520,"type":23},"2026-11",{"name":52,"class":53},{"id":523,"slug":4,"hasResults":11,"nctId":524,"briefTitle":525,"officialTitle":526,"acronym":527,"eligibilityCriteria":528,"healthyVolunteers":11,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":529,"targetDuration":4,"studyType":24,"phases":531,"briefSummary":532,"conditions":533,"keywords":535,"overallStatus":42,"whyStopped":4,"lastUpdateSubmitDate":516,"lastUpdatePostDateStruct":540,"startDateStruct":541,"completionDateStruct":543,"leadSponsor":544,"locationsCount":104},"100569393","NCT06693661","Collaborative Learning to Achieve Refined Interventions for Emory: Kidney Disease","Improving Access to Nephrology Treatment and Care Among Patients at Greatest Risk for Kidney Failure","CLARIFy-KD","Inclusion Criteria:\n\n* Identifies as African American or Black\n* Two estimated glomerular filtration rates (eGFRs) \\\u003C 29 separated by at least 90 days but within the past 2 years, or a Kidney Failure Risk Equation (KFRE) score of 10% or greater likelihood of kidney failure within the next 2 years\n* Had an encounter at Emory Healthcare through an ambulatory visit or inpatient stay (i.e., ER or hospital visit within the previous 2 months\n* Stated willingness to comply with all study procedures and availability for the duration of the study\n\nExclusion Criteria:\n\n* Currently on dialysis\n* currently receiving hospice care or other types of conservative management for terminal illness\n* Currently on waitlist, or referred for\u002For completed a transplant evaluation visit within the past 2 years\n* Kidney or another solid organ transplant\n* Active cancer treatment\n* Non-English speaking\n* Participating in another treatment or intervention study at the time of enrollment\n* Currently pregnant or planning to become pregnant at the time of recruitment",{"count":530,"type":23},600,[26],"Through the use of community-engaged processes, this project seeks to develop and implement clinical decision support (CDS) and a kidney health coaching (KHC) intervention. The CDS seeks to streamline workflows to effectively screen, identify, and link to care for those patients with advanced chronic kidney disease (CKD).\n\nThe overall project goals are to 1.) Design and conduct community-engaged clinical trials to test new interventions that dismantle the systemic factors that contribute to kidney health disparities. 2.) Foster research collaborations between investigators, people living with kidney disease, community-based organizations, and other key stakeholders.\n\nResearchers aim to assess whether the KHC intervention is effective at delaying the transition to kidney replacement therapy (KRT) and central venous catheter use or death.",[534],"Kidney Diseases",[536,537,538,539],"African American","Health Disparities","Chronic Care Model (CCM)","Kidney Health Coach (KHC)",{"date":496,"type":46},{"date":542,"type":46},"2026-03-10",{"date":102,"type":23},{"name":52,"class":53},{"id":546,"slug":4,"hasResults":11,"nctId":547,"briefTitle":548,"officialTitle":549,"acronym":4,"eligibilityCriteria":550,"healthyVolunteers":11,"sex":475,"minAge":19,"maxAge":4,"enrollmentInfo":551,"targetDuration":4,"studyType":24,"phases":553,"briefSummary":555,"conditions":556,"keywords":4,"overallStatus":42,"whyStopped":4,"lastUpdateSubmitDate":516,"lastUpdatePostDateStruct":562,"startDateStruct":563,"completionDateStruct":565,"leadSponsor":567,"locationsCount":104},"100496202","NCT05741164","Propranolol and Pembrolizumab for Tumor Re-sensitization and Treatment of Patients With Checkpoint Inhibitor Refractory Metastatic or Unresectable Triple Negative Breast Cancer","Impact of Beta-2 Adrenergic Blockade With Checkpoint Inhibition in Checkpoint Inhibitor Refractory Metastatic Triple Negative Breast Cancer","Inclusion Criteria:\n\n* Age \\>= 18 years of age\n* Have pathologically confirmed diagnosis of unresectable or metastatic triple negative breast cancer (TNBC) with no curative treatment options\n* No chemotherapy, radiotherapy, or major surgery within 4 weeks of protocol treatment\n* Checkpoint inhibitor refractory patients (i.e., no longer responding to chemotherapy and checkpoint inhibitor) who have disease progression on prior line of chemotherapy and pembrolizumab, and, who in the opinion of the physician, can continue checkpoint inhibitor\n* Patients must be agreeable to pre- and 6-week post treatment biopsy in part 1 of the study\n\n  * The pre-treatment biopsy for this study must be taken at least 4 weeks after all previous chemotherapy (pembrolizumab is allowed during this period)\n* Participants of child-bearing potential must agree to use adequate contraceptive methods (e.g. hormonal or barrier method of birth control; abstinence) prior to study entry. Should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately\n* Have an Eastern Cooperative Oncology Group (ECOG) Performance Status of =\\\u003C 1\n* Platelets \\>= 100,000\u002FuL\n* Hemoglobin \\>= 9.0 g\u002FdL\n* Absolute neutrophil count (ANC) \\>= 1500\u002FuL\n* Total bilirubin =\\\u003C institutional upper limit of normal (ULN)\n* Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase \\[SGOT\\]) and alanine aminotransferase (ALT) (serum glutamic pyruvic transaminase \\[SGPT\\]) =\\\u003C 2.5 X institutional ULN\n* Creatinine clearance \\>= 50 mL\u002Fmin per Cockcroft-Gault equation\n* HbA1C \\\u003C=8.5\n* Have measurable disease per RECIST 1.1 criteria present\n* Ability to swallow and retain oral medication\n* Participant must understand the investigational nature of this study and sign an Independent Ethics Committee\u002FInstitutional Review Board approved written informed consent form prior to receiving any study related procedure\n\nExclusion Criteria:\n\n* Patients currently treated with systemic immunosuppressive agents, including steroids, are ineligible until 3 weeks after removal from immunosuppressive treatment\n* Patients with active autoimmune disease, requiring ongoing immunosuppressive therapy or history of transplantation\n* Patients with rapidly progressive disease\u002F symptomatic disease\n* Patients with primary resistance (i.e., did not respond to initial treatment with chemotherapy plus checkpoint inhibitor) with progressive disease at 12 weeks after starting chemotherapy and pembrolizumab\n* Patients who are pregnant or nursing. Women of childbearing potential (WOCBP) will have to undergo a urine pregnancy test as part of screening\n* Participants with symptomatic known brain metastases \\\u003C 4 weeks from radiation treatment should be excluded from this clinical trial because of their poor prognosis and because they often develop progressive neurologic dysfunction that would confound the evaluation of neurologic and other adverse events\n* History of malignancy other than breast cancer within 5 years prior to screening, with the exception of those with a negligible risk of metastases or death\n* Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness\u002Fsocial situations that would limit compliance with study requirements\n* Unwilling or unable to follow protocol requirements\n* Contraindications to the use of beta-blockers, like: uncontrolled depression, unstable angina pectoris, uncontrolled heart failure (grade III or IV), hypotension (systolic blood pressure \\\u003C 100 mmHg), severe asthma or chronic obstructive pulmonary disease (COPD), uncontrolled type I or type II diabetes mellitus (hemoglobin A1C \\[HbA1C\\] \\> 8.5 or fasting plasma glucose \\> 160 mg\u002Fdl at screening), symptomatic peripheral arterial disease or Raynaud's syndrome, untreated pheochromocytoma, current use of beta-blockers or non-dihydropyridine calcium channel blockers\n* Any additional condition which in the investigator's opinion deems the participant an unsuitable candidate to receive the study drugs",{"count":552,"type":23},37,[554],"PHASE2","This phase II trial tests how well propranolol and pembrolizumab work to cause tumor re-sensitization and therefore treatment in patients with triple negative breast cancer that has not responded to previous checkpoint inhibitor therapy (refractory), cannot be removed by surgery (unresectable) or has spread from where it first started (primary site) to other places in the body (metastatic). Propranolol is a drug that is classified as a beta-blocker. Beta-blockers affect the heart and circulation. Beta-blockers, like propranolol, may help to counteract effects of certain stress hormones produced by the body during cancer treatment and may increase the effectiveness of the pembrolizumab. Pembrolizumab is a drug that is classified as an immune checkpoint inhibitor. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Propranolol may be able to re-sensitize the cells of the immune system to respond to the checkpoint inhibitor pembrolizumab in patients with checkpoint inhibitor refractory metastatic or unresectable triple negative breast cancer.",[557,558,559,560,561],"Anatomic Stage III Breast Cancer AJCC v8","Anatomic Stage IV Breast Cancer AJCC v8","Metastatic Triple-Negative Breast Carcinoma","Refractory Triple-Negative Breast Carcinoma","Unresectable Triple-Negative Breast Carcinoma",{"date":496,"type":46},{"date":564,"type":46},"2024-09-01",{"date":566,"type":23},"2029-06-30",{"name":52,"class":53},{"id":569,"slug":4,"hasResults":11,"nctId":570,"briefTitle":571,"officialTitle":572,"acronym":4,"eligibilityCriteria":573,"healthyVolunteers":17,"sex":18,"minAge":574,"maxAge":575,"enrollmentInfo":576,"targetDuration":4,"studyType":134,"phases":4,"briefSummary":578,"conditions":579,"keywords":581,"overallStatus":42,"whyStopped":4,"lastUpdateSubmitDate":588,"lastUpdatePostDateStruct":589,"startDateStruct":590,"completionDateStruct":592,"leadSponsor":593,"locationsCount":104},"100509669","NCT05916430","Screening for Autism in 9-Month-Olds by Measuring Social Visual Engagement","Community-viable Screening for Autism Spectrum Disorder (ASD) in 9-month-old Infants Using Quantitative Eye-tracking Assays of Social Visual Engagement","Inclusion Criteria:\n\n* Infants between the chronological ages of 8-10 months\n* Infants must be generally healthy with no acute illnesses likely to prevent successful or valid data collection (e.g., current vomiting, high fever, conjunctivitis affecting vision)\n* Participants' parents\u002Fcaregivers must be able to understand and voluntarily provide written informed consent.\n\nExclusion Criteria:\n\n\\- Children will be excluded if they have signs of acute illness likely to prevent successful or valid data collection (e.g., conjunctivitis affecting vision, current vomiting, or high fever).","8 Months","10 Months",{"count":577,"type":23},2120,"The goal of this project is to measure the clinical utility of an objective and quantitative eye-tracking assay collected on a standalone, mobile investigational device to accurately screen 9-month-old infants for autism spectrum disorder and other actionable delays.",[459,580],"Infant Development",[582,583,584,585,586,587],"Screening","well-baby visits","Social Development","Communicative Development","Development Disabilities","Autism Spectrum Disorders","2026-06-02",{"date":496,"type":46},{"date":591,"type":46},"2023-02-02",{"date":444,"type":23},{"name":52,"class":53},{"id":595,"slug":4,"hasResults":11,"nctId":596,"briefTitle":597,"officialTitle":597,"acronym":598,"eligibilityCriteria":599,"healthyVolunteers":17,"sex":18,"minAge":85,"maxAge":4,"enrollmentInfo":600,"targetDuration":4,"studyType":24,"phases":601,"briefSummary":602,"conditions":603,"keywords":605,"overallStatus":42,"whyStopped":4,"lastUpdateSubmitDate":249,"lastUpdatePostDateStruct":609,"startDateStruct":610,"completionDateStruct":612,"leadSponsor":614,"locationsCount":54},"100638705","NCT07629739","Inspiring Seniors Towards Exercise Promotion - 2","iSTEP-2","Inclusion Criteria:\n\n* Adults over 65 years old.\n* Ambulatory without pain or the use of assisted walking devices.\n* Able to speak and read English.\n* Healthy enough to exercise at moderate intensity with or without medical clearance by a primary care physician.\n* Living in the community for the duration of the study (9-10 months).\n* Having a reliable means of transportation.\n* Having a safe place at home or at a residential area (at least 6 feet by 6 feet of open space) for unsupervised exercise training.\n* Being low-active (\\\u003C 90 min\u002Fweek of MAT and \\\u003C 2 days\u002Fweek of ST for the last 3 months).\n\nExclusion Criteria:\n\n* Concurrent diagnosis of neurological disorder (e.g., dementia, Parkinson's disease, multiple sclerosis, etc.), determined by self-report on the Physical Activity Readiness Questionnaire for Everyone (PAR-Q+).\n* Known exercise contraindications (uncontrolled hypertension, joint problems, diabetes, metabolic conditions, etc.), determined by self-report on the PAR-Q+.\n* Current or upcoming cancer treatment, determined by self-report on the PAR-Q+.\n* Stroke or neural impairment in the past 6 months, as self-reported on the PAR-Q+.\n* Hip\u002Fknee\u002Fspinal fracture or surgery in the past 6 months, determined by self-report on the ACSM Health Screening Questionnaire.\n* Unable or unwilling to attend intervention classes, as determined by phone screening.\n* Currently participating in any other exercise or fitness-related research study, determined by phone screening.\n* Use of medications for cognitive impairment, as self-reported on the medication survey.\n* Change in dosage of medications prescribed for anxiety or depression within the previous 6 months, determined by self-report on a medication form.\n* Self-report regularly drinking \\> 14 alcoholic beverages a week or current illicit drug use, determined by self-report to screening surveys.\n* Cannot ambulate without a walker\u002Fcane, assessed in the American College of Sports Medicine (ACSM) Health Screening Questionnaire\n\n  • Having cognitive impairment, determined by the Montreal Cognitive Assessment (MoCA) BLIND \\\u003C 17.\n* Meet the threshold for clinical depression, determined by the Center for Epidemiological Studies Depression Scale Revised (CESD-R).\n* Uncorrected hearing or visual impairments, self-reported on the Health History Questionnaire.\n* Unable to understand the study procedure.\n* One of the household members is participating in this study, as self-reported during phone screening.",{"count":240,"type":23},[26],"Older adults' low adherence to the national physical activity guidelines may stem from a failure to increase positive affective responses to exercise (e.g., enjoyment). Exercising with personalized, tempo-synchronous music playlists has shown promising effects on physical activity promotion in midlife-to-older adults during a cardiac rehab program. The purpose of this study is to determine how personalized, tempo-synchronous music playlists called rhythmic auditory stimulation (RAS) influence exercise behavior change and affective responses to exercise over 8 months among community-dwelling, sedentary older adults.",[604],"Old Age",[606,607,34,608],"Physical Activity","Exercise","Cognitive decline prevention",{"date":227,"type":46},{"date":611,"type":46},"2026-05-26",{"date":613,"type":23},"2028-08",{"name":52,"class":53},""]